JOHN JOHNSON - 08 Dec 2025 Form 4 Insider Report for Axogen, Inc. (AXGN)

Role: Director
Signature: /S/ Marc Began, as attorney-in-fact for John Johnson
Issuer symbol: AXGN
Transactions as of: 08 Dec 2025
Net transactions value: -$1,261,646
Form type: 4
Filing time: 10 Dec 2025, 17:19:01 UTC
Previous filing: 15 Aug 2025
Next filing: 19 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
JOHNSON JOHN	Director	C/O AXOGEN, INC. 13631 PROGRESS BLVD., SUITE 400, ALACHUA	/S/ Marc Began, as attorney-in-fact for John Johnson	10 Dec 2025	0001410781

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AXGN	Common Stock	Sale	$368,931	-11,802	-47%	$31.26	13,141	08 Dec 2025	Direct	F1
transaction	AXGN	Common Stock	Options Exercise	$74,913	+11,891	+90%	$6.30	25,032	08 Dec 2025	Direct
transaction	AXGN	Common Stock	Sale	$371,273	-11,891	-48%	$31.22	13,141	08 Dec 2025	Direct	F1
transaction	AXGN	Common Stock	Options Exercise	$53,834	+8,545	+65%	$6.30	21,686	09 Dec 2025	Direct
transaction	AXGN	Common Stock	Sale	$256,196	-8,545	-39%	$29.98	13,141	09 Dec 2025	Direct	F2
transaction	AXGN	Common Stock	Sale	$393,993	-13,141	-100%	$29.98	0	09 Dec 2025	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AXGN	Stock Option (right to purchase)	Options Exercise	$0	-11,891	-58%	$0.000000	8,545	08 Dec 2025	Common Stock	11,891	$6.30	Direct	F4
transaction	AXGN	Stock Option (right to purchase)	Options Exercise	$0	-8,545	-100%	$0.000000	0	09 Dec 2025	Common Stock	8,545	$6.30	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.98 to $30.02 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3	The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.90 to $30.09 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4	Non-qualified stock option portion of the 2023 annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The grant became fully vested on September 1, 2024, the one-year anniversary of the grant date.